Kyverna Therapeutics, Inc. SEC filings KYTX
Kyverna Therapeutics, Inc. has 187 filings in SEC EDGAR's recent list, going back to Oct 5, 2023. Its latest annual report, Form ARS, was filed on Apr 13, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 24, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| SCHEDULE 13G | Ownership over 5% (passive) | Oct 19, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Aug 14, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Jul 29, 2026 | — |
| 4 | Insider transaction | May 29, 2026 | May 27, 2026 |
| 4 | Insider transaction | May 29, 2026 | May 27, 2026 |
| 4 | Insider transaction | May 29, 2026 | May 27, 2026 |
| 4 | Insider transaction | May 29, 2026 | May 27, 2026 |
| 4 | Insider transaction | May 29, 2026 | May 27, 2026 |
| 4 | Insider transaction | May 20, 2026 | May 18, 2026 |
| 3 | Initial insider ownership | May 20, 2026 | May 18, 2026 |
| 4 | Insider transaction | May 6, 2026 | May 4, 2026 |
| 3 | Initial insider ownership | May 6, 2026 | May 4, 2026 |
| 144 | Notice of proposed sale | Apr 17, 2026 | — |
| 144 | Notice of proposed sale | Apr 14, 2026 | — |
| 144 | Notice of proposed sale | Apr 7, 2026 | — |
| 144 | Notice of proposed sale | Mar 31, 2026 | — |
| 4 | Insider transaction | Mar 17, 2026 | Mar 13, 2026 |
| 4 | Insider transaction | Mar 17, 2026 | Mar 13, 2026 |
| 4 | Insider transaction | Mar 17, 2026 | Mar 13, 2026 |
| 3 | Initial insider ownership | Mar 4, 2026 | Feb 24, 2026 |
| 4 | Insider transaction | Mar 4, 2026 | Feb 24, 2026 |
| 4 | Insider transaction | Feb 26, 2026 | Feb 24, 2026 |
| 3 | Initial insider ownership | Feb 26, 2026 | Feb 24, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 17, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 17, 2026 | — |
| 3 | Initial insider ownership | Feb 11, 2026 | Feb 9, 2026 |
| 4 | Insider transaction | Feb 11, 2026 | Feb 9, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 6, 2026 | — |
| 4 | Insider transaction | Jan 14, 2026 | Jan 12, 2026 |
| 4 | Insider transaction | Dec 22, 2025 | Dec 18, 2025 |
| 4 | Insider transaction | Dec 22, 2025 | Dec 18, 2025 |
| 4 | Insider transaction | Dec 17, 2025 | Dec 15, 2025 |
| 144 | Notice of proposed sale | Dec 15, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Nov 17, 2025 | — |
| 4 | Insider transaction | Jul 1, 2025 | Jun 30, 2025 |
| 3 | Initial insider ownership | Jul 1, 2025 | Jun 30, 2025 |
| 4 | Insider transaction | Jun 2, 2025 | May 29, 2025 |
| 4 | Insider transaction | Jun 2, 2025 | May 29, 2025 |
| 4 | Insider transaction | Jun 2, 2025 | May 29, 2025 |
| 4 | Insider transaction | Jun 2, 2025 | May 29, 2025 |
| 4 | Insider transaction | Jun 2, 2025 | May 29, 2025 |
| 4 | Insider transaction | Jun 2, 2025 | May 29, 2025 |
| 4 | Insider transaction | Apr 15, 2025 | Apr 11, 2025 |
| 4 | Insider transaction | Apr 15, 2025 | Apr 11, 2025 |
| 4 | Insider transaction | Apr 15, 2025 | Apr 11, 2025 |
| 4 | Insider transaction | Feb 19, 2025 | Feb 14, 2025 |
| 4 | Insider transaction | Jan 24, 2025 | Jan 22, 2025 |
| 3 | Initial insider ownership | Jan 24, 2025 | Jan 22, 2025 |
| SC 13G | Ownership over 5% (passive) | Nov 12, 2024 | — |
| 4 | Insider transaction | Oct 24, 2024 | Oct 21, 2024 |
| 3 | Initial insider ownership | Oct 24, 2024 | Oct 21, 2024 |
| SC 13G | Ownership over 5% (passive) | Oct 10, 2024 | — |
| 4 | Insider transaction | Sep 18, 2024 | Sep 16, 2024 |
| 4 | Insider transaction | Sep 18, 2024 | Sep 16, 2024 |
| 3 | Initial insider ownership | Sep 18, 2024 | Sep 16, 2024 |
| 3 | Initial insider ownership | Sep 18, 2024 | Sep 16, 2024 |
| 4 | Insider transaction | Jun 10, 2024 | Jun 6, 2024 |
| 4 | Insider transaction | May 29, 2024 | May 28, 2024 |
| SC 13D | Ownership over 5% (active) | May 3, 2024 | — |
| SC 13G | Ownership over 5% (passive) | Feb 22, 2024 | — |
| SC 13G | Ownership over 5% (passive) | Feb 20, 2024 | — |
| 4 | Insider transaction | Feb 14, 2024 | Feb 12, 2024 |
| 4 | Insider transaction | Feb 14, 2024 | Feb 12, 2024 |
| 4 | Insider transaction | Feb 14, 2024 | Feb 12, 2024 |
| 4 | Insider transaction | Feb 14, 2024 | Feb 12, 2024 |
| 4 | Insider transaction | Feb 14, 2024 | Feb 12, 2024 |
| SC 13G | Ownership over 5% (passive) | Feb 14, 2024 | — |
| 4 | Insider transaction | Feb 13, 2024 | Feb 12, 2024 |
| 4 | Insider transaction | Feb 12, 2024 | Feb 12, 2024 |
| 3 | Initial insider ownership | Feb 8, 2024 | Feb 7, 2024 |
| 3 | Initial insider ownership | Feb 8, 2024 | Feb 7, 2024 |
| 3 | Initial insider ownership | Feb 7, 2024 | Feb 7, 2024 |
| 3 | Initial insider ownership | Feb 7, 2024 | Feb 7, 2024 |
| 3 | Initial insider ownership | Feb 7, 2024 | Feb 7, 2024 |
| 3 | Initial insider ownership | Feb 7, 2024 | Feb 7, 2024 |
| 3 | Initial insider ownership | Feb 7, 2024 | Feb 7, 2024 |
| 3 | Initial insider ownership | Feb 7, 2024 | Feb 7, 2024 |
| 3 | Initial insider ownership | Feb 7, 2024 | Feb 7, 2024 |
| 3 | Initial insider ownership | Feb 7, 2024 | Feb 7, 2024 |
| 3 | Initial insider ownership | Feb 7, 2024 | Feb 7, 2024 |
| 3 | Initial insider ownership | Feb 7, 2024 | Feb 7, 2024 |
| 3 | Initial insider ownership | Feb 7, 2024 | Feb 7, 2024 |
| 3 | Initial insider ownership | Feb 7, 2024 | Feb 7, 2024 |
| 3 | Initial insider ownership | Feb 7, 2024 | Feb 7, 2024 |
| 3 | Initial insider ownership | Feb 7, 2024 | Feb 7, 2024 |
| 3 | Initial insider ownership | Feb 7, 2024 | Feb 7, 2024 |
Showing 86 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- KYTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Emeryville, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1994702
- Former names
- Kyverna Therapeutics, Inc. (until Oct 19, 2026)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.